Healthcare / Medical DevicesNasdaqCM
$0.90
+0.02 (+2.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-3.6M · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-54.3%
↓Gross Margin
6.0%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
+25.9%
FCF CAGR
—
FCF margin
-369.4%
FCF / Net income
0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.6M · net income $-18.2M · FCF $-9.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $2.6M | $2.6M | $2.6M | $2.3M | $752000.00 | $1.7M | $623000.00 | $530000.00 | $318000.00 | $239000.00 | $229000.00 | $147000.00 | $203000.00 |
| Net Income | $-18.2M | $-18.2M | $-3.7M | $-3.7M | $-5.4M | $-14.3M | $-4.3M | $-5.8M | $-4.2M | $-5.0M | $-2.8M | $-2.9M | $-2.6M |
| EBITDA | $-10.8M | $-10.8M | $-3.6M | $-3.5M | $-5.1M | $-5.7M | $-4.7M | $-5.1M | $-4.3M | — | — | — | — |
| EPS | -26.69 | -26.69 | -137.30 | -233.20 | -422.40 | -1248.50 | — | — | — | — | — | — | — |
| Gross Margin | 6.0% | 6.0% | 59.0% | 67.3% | 22.2% | 45.4% | 34.3% | 53.0% | 50.3% | 63.2% | 61.6% | 66.7% | 54.2% |
| Operating Margin | -459.7% | -459.7% | -140.0% | -150.5% | -666.5% | -335.3% | -757.5% | -971.9% | -1353.1% | -1293.3% | -1011.4% | -968.7% | -596.6% |
| Net Margin | -712.3% | -712.3% | -144.8% | -162.5% | -724.5% | -842.6% | -694.4% | -1093.2% | -1306.3% | -2077.4% | -1236.2% | -1961.9% | -1303.9% |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.04 | 0.04 | 0.19 | 0.00 | 0.03 | — | — | — | — | — | — | — | — |
| Current Ratio | 0.90 | 0.90 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-9.4M | $-9.4M | $-2.5M | $-3.6M | $-7.0M | $-4.4M | $-3.4M | — | $-3.6M | — | $-1.5M | — | — |
| Returns | |||||||||||||
| ROE | -54.3% | -54.3% | -590.9% | -93.1% | -168.5% | -226.2% | -180.7% | -430.1% | -897.2% | -136.6% | 113.3% | 1379.9% | 47.1% |
| Valuation | |||||||||||||
| P/B | 0.02 | 0.02 | 2.85 | 0.45 | 2.42 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | -0.2% | -0.2% | 12.0% | 203.6% | — | 172.1% | 17.5% | 66.7% | 33.1% | 4.4% | 55.8% | -27.6% | — |
| EPS Growth | 80.6% | 80.6% | 41.1% | 44.8% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-137.30 → -26.69
Residual
-91.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.